Compare MDXH & CFND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MDXH | CFND |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Belgium | |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 23.8M |
| IPO Year | 2021 | 2025 |
| Metric | MDXH | CFND |
|---|---|---|
| Price | $0.48 | $3.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 772.9K | 36.6K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $2.85 |
| 52 Week High | $5.33 | $9.67 |
| Indicator | MDXH | CFND |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 54.30 |
| Support Level | N/A | $3.18 |
| Resistance Level | $3.79 | $3.53 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 47.66 | 74.60 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.